Inc.

Stem, Inc. (STEM) Investor Alert: Investors Who Lost Over $100,000 Should Contact Robbins LLP for Information About Leading the Securities Class Action Your Rights Against Stem, Inc. f/k/a Star Peak Energy Transition Corp.

Retrieved on: 
Thursday, June 1, 2023
LLP, Partnership, AP, SAN, STEM, News, NYSE, Software, Cryptocurrency, Security (finance), Stem, Inc.

Stem purports to operate as a digitally connected and intelligent energy storage network provider in the U.S. and internationally.

Key Points: 
  • Stem purports to operate as a digitally connected and intelligent energy storage network provider in the U.S. and internationally.
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call (800) 350-6003.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • If you choose to take no action, you can remain an absent class member.

Virtu Financial, Inc. (VIRT) Investor Alert: Robbins LLP Urges Shareholders to Contact the Firm for Information About Virtu Financial, Inc. Securities Class Action

Retrieved on: 
Wednesday, May 31, 2023
Complaint, Virtu Financial, LLP, Wells notice, News, SAN, Virtu, Person, Security (finance), Inc.

For more information, submit a form , email Aaron Dumas, Jr., or give us a call (800) 350-6003.

Key Points: 
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call (800) 350-6003.
  • On February 17, 2023, Virtu reported that "the Company has been responding to requests for information from the U.S. Securities and Exchange Commission in connection with an investigation of aspects of the Company's information access barriers."
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Virtu Financial, Inc. Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Beyond Meat, Inc. (BYND) Securities Fraud Class Action: Investors Should Contact Robbins LLP About Their Rights Against Beyond Meat, Inc.

Retrieved on: 
Wednesday, May 31, 2023
LLP, Meat, KFC, Starbucks, Beyond Meat, Key, BYND, Complaint, Taco Bell, Pizza Hut, McDonald's, SAN, News, Scale, Security (finance), Fast food, Inc.

For more information, submit a form , email Aaron Dumas, Jr., or give us a call (800) 350-6003.

Key Points: 
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call (800) 350-6003.
  • In truth, Beyond Meat was unable to manufacture its meat substitutes at scale to the specifications of its partners.
  • Further, Beyond Meat suffered from widespread scaling issues, particularly misalignment and delayed decision-making, which led to corresponding production delays.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Cutera, Inc. (CUTR) Shareholder Notice: Robbins LLP Reminds Investors of Class Action Against Cutera, Inc.

Retrieved on: 
Tuesday, May 30, 2023
Disclosure, LLP, Annual report, Failure, SAN, Person, Security (finance), Inc.

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Cutera, Inc. (NASDAQ: CUTR) common stock between February 17, 2021 and May 9, 2023.

Key Points: 
  • SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Cutera, Inc. (NASDAQ: CUTR) common stock between February 17, 2021 and May 9, 2023.
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call (800) 350-6003.
  • What is this Case About: Cutera, Inc. (CUTR) Misled Investors Regarding its Internal Controls Over Financial Reporting
    Beginning on January 9, 2023, investors began to learn the truth.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Kenvue to Participate in the Deutsche Bank dbAccess Global Consumer Conference on June 8, 2023

Retrieved on: 
Wednesday, May 31, 2023
Medical Supplies, Retail, Health, Other Consumer, Consumer, Other Retail, Other Health, KVUE, Central European, Inc., Conference, NYSE, Film industry

Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced the company’s participation in Deutsche Bank’s dbAccess Global Consumer Conference 2023 in Paris.

Key Points: 
  • Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced the company’s participation in Deutsche Bank’s dbAccess Global Consumer Conference 2023 in Paris.
  • Chief Executive Officer and Director, Thibaut Mongon, and Chief Financial Officer, Paul Ruh, will participate in a fireside chat on Thursday, June 8, 2023, at 12:30 p.m. Central European Summer Time (6:30 a.m.
  • ET).
  • A live webcast of the session will be available at https://investors.kenvue.com and a replay will be available on the website following the event.

Kardium Announces First US Procedures in PULSAR Study of Globe® Pulsed Field System

Retrieved on: 
Wednesday, May 31, 2023
Cardiology, Biotechnology, Health, General Health, Pharmaceutical, Other Science, Medical Devices, Research, Hospitals, Science, Clinical Trials, McGill University Health Centre, Heart, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Inc., EU, Vein, Atrial fibrillation, Mount Sinai Hospital (Manhattan), PFA, Sale, Trial of the century, Electrode, Gold, Mount Sinai Hospital, MD, Patient, Mount, AF, IDE, FDA, Food, Safety, Medical device

The PULSAR study will enroll over 400 patients for treatment at up to 35 sites in the United States, Canada, and Europe.

Key Points: 
  • The PULSAR study will enroll over 400 patients for treatment at up to 35 sites in the United States, Canada, and Europe.
  • The study expands on the successful Globe System PULSE-EU study of 69 patients treated in Prague, Czech Republic.
  • “As a next generation pulsed field system, the Globe System allows precise delivery of pulsed field energy.
  • Kardium Inc. (kardium.com) is a rapidly growing, privately held medical solutions company that has developed an advanced system for atrial fibrillation (AF) treatment: the Globe® System.

Hudl, Ballogy Team Up To Deliver Innovative Player Development To Basketball Programs Everywhere

Retrieved on: 
Wednesday, May 31, 2023
Basketball, Apps, Applications, Technology, Other Sports, Sports, General Sports, Other Technology, Software, Internet, Data Management, Inc., Partnership, BSA, D1, Curriculum, Athlete, Strategic partnership, Junior college, Hudl, NAIA, Sport

Ballogy Inc. , the leading skills development and assessment platform for youth and amateur basketball players, announced today a partnership with Hudl, the pioneer in performance analysis technology.

Key Points: 
  • Ballogy Inc. , the leading skills development and assessment platform for youth and amateur basketball players, announced today a partnership with Hudl, the pioneer in performance analysis technology.
  • Hudl coaches, teams, and players can access Ballogy’s monthly training and development curriculum endorsed by the National High School Basketball Coaches Association (NHSBCA).
  • Designed to promote healthy competition, accountability, and overall skill development, the curriculum includes beginner, intermediate, and advanced levels of player development, easily accessible and administered by coaches from the Ballogy mobile app.
  • “With Hudl’s complete suite of video and data products combined with Ballogy’s player development platform, coaches now have all the resources and insights they need at their fingertips.

Hemodialysis Technology Company Diality Names Robert Funari to its Board of Directors

Retrieved on: 
Wednesday, May 31, 2023
Nursing, Medical Devices, Health, Hospitals, Health Technology, Managed Care, Fresenius Medical Care, Inc., Cardinal, Baxter International, Dialysis, Funari, Cardinal Health, Acquisition, Knowledge, Kidney disease, Management, Mail order, MD

Diality Inc. , a medical technology company developing a smart, flexible hemodialysis platform, today announced the appointment of healthcare veteran Robert Funari to its board of directors.

Key Points: 
  • Diality Inc. , a medical technology company developing a smart, flexible hemodialysis platform, today announced the appointment of healthcare veteran Robert Funari to its board of directors.
  • Funari has spent nearly 50 years in the healthcare industry in public and privately held companies, in both services and medical devices.
  • He was chairman of hemodialysis technology company NxStage Medical until its 2019 acquisition by Fresenius Medical Care.
  • “We thank Aaron for his dedicated service at Diality, and wish him well in his future endeavors,” Khawar said.

Myrtelle to Present Positive 6-month Post-Treatment Data in Its First-in-Human Clinical Study of rAAV-Olig001-ASPA Gene Therapy in Canavan Disease at the National Tay-Sachs and Allied Diseases Annual Family Conference

Retrieved on: 
Wednesday, May 31, 2023
Neurology, Biotechnology, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Other Health, CD, Gross, Canavan disease, Inc., Drug development, Natural history, IV, Clinical trial, Mutation, Human, Brain, ASPA, AAV, Doctor of Philosophy, Language, NAA, System, MRI, MRS, Magnetic resonance imaging, Metabolism, MD, Patient, Preyasi Raave, White matter, CSF, FIH, Conference, Caregiver, Vaccine, Medical imaging, Myrtelle Canavan

Olga Flamini, MD, PhD, Medical Director at Myrtelle, will deliver a presentation on Friday, June 2, 2023.

Key Points: 
  • Olga Flamini, MD, PhD, Medical Director at Myrtelle, will deliver a presentation on Friday, June 2, 2023.
  • These improvements in treated patients contrast the deterioration in untreated age-matched CD patients in Myrtelle’s natural history data set.
  • In CD, normal brain development is impaired due to a mutation in the ASPA gene that encodes the enzyme aspartoacylase.
  • “Connecting with patients and caregivers allows us to incorporate the patient voice into our drug development activities.”

Liberate Bio Announces Expansion of its Leadership Team

Retrieved on: 
Wednesday, May 31, 2023
Health, Biotechnology, Drug, Amgen, Therapy, Drug delivery, Sirna Therapeutics, Research, Merck & Co., Antibody, AstraZeneca, Intellia Therapeutics, Dicarboxylic acid, Patient, Inc., Liberation, Pharmaceutical industry

Liberate Bio., a biotech company focused on identifying and developing new vehicles to deliver oligonucleotide cargos, announced the expansion of its leadership team.

Key Points: 
  • Liberate Bio., a biotech company focused on identifying and developing new vehicles to deliver oligonucleotide cargos, announced the expansion of its leadership team.
  • Dr. Shawn Davis has joined Liberate as Chief Executive Officer, and Dr. Walter R. Strapps has joined Liberate as Chief Scientific Officer.
  • He joined Liberate Bio from AstraZeneca, where he was the Head of Drug Delivery for R&D Biopharmaceutical Development.
  • “The opportunity to lead the talented team at Liberate Bio to realize the full potential of genetic medicines through targeted delivery to any organ of the body is thrilling.